🇺🇸 FDA
Pipeline program

CINRYZE

0624-203

Phase 2 mab completed

Quick answer

CINRYZE for Hereditary Angioedema (HAE) is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hereditary Angioedema (HAE)
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials